{"id":"a223016ba731","type":"article","url":"https://hartvaat.nl/2025/01/01/vasculaire-disfunctie-in-de-cardio-oncologie-hormoonstatus-chemotherapie-en-risi/","title":"Vasculaire disfunctie in de cardio-oncologie: hormoonstatus, chemotherapie en risico","title_en":"Vascular Dysfunction in Cardio-Oncology: Hormone Status, Chemotherapy, and Risk","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","internist"],"tags":["kanker-en-hart"],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109725103562?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109725103562?dgcid=rss_sd_all","authors":["Julia Bertazzo","Caitlin F. Bell"],"significance":7,"published":"2026-03-01","source_date":"2025-01-01","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"","summary_en":"This JACC review examined vascular dysfunction in cardio-oncology, focusing on how hormonal status and chemotherapy agents contribute to cardiovascular risk in cancer patients and survivors.","created":"2026-07-03T10:25:44Z","updated":"2026-07-03T13:25:07Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Bespreking in JACC over vasculaire disfunctie in de cardio-oncologie, met nadruk op de rol van hormoonstatus en chemotherapie als risicofactoren voor cardiovasculaire schade bij kankerpatiënten.","abstract_original":"Publication date: 17 February 2026Source: JACC, Volume 87, Issue 6"}